

Special Issue

Targeting Tumor Niches for Cancer Chemoprevention and Treatment

Message from the Guest Editors

Tumor niches are microanatomical compartments within the tumor microenvironment (TME) that regulate metabolic needs, immune surveillance, survival, tumor invasion, and cancer stem cell (CSC) maintenance. Although significant advances have been made in understanding the role of tumor niches and/or TME in tumor growth and metastasis, the application of cancer chemoprevention to control the tumor niches and/or TME during the early stages of carcinogenesis as well as targeted therapy response and prognosis have not received concerted attention. Tumor niches and TME in general also contribute to tumor heterogeneity, lineage plasticity, and response to therapy. While most preventive and treatment efforts are directed at controlling cancer cell dysfunction, the contribution of the TME to malignant behaviors, treatment response, and metastasis is an area of active research. This Special Issue aims to highlight the role of tumor niches and TME in cancer chemoprevention and therapy response, covering both basic and clinical aspects, including diet-induced chemoprevention, chemotherapy and radiation therapy response, and any related biomarkers in different types of cancers.

Guest Editors

Prof. Dr. Vinata B.L. Lokeshwar
Prof. Dr. Balakrishna (Bal) L. Lokeshwar
Dr. Thangaraju Muthusamy

Deadline for manuscript submissions

closed (30 June 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/121198

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)